Our Mission
At Biobot Surgical, our mission is to revolutionize the realm of robotic-assisted biopsy and treatment for prostate cancer.
As the landscape for prostate cancer treatment evolves, we aren’t just riding this wave of change — we’re propelling it, ushering in a new era of excellence in prostate disease management. At the forefront of these advances in the standard of care in prostate cancer management, we are poised to address the global unmet need for a precision percutaneous approach to transperineal procedures — and make a monumental impact on the lives of patients.
Our Story
Biobot Surgical is the first surgical robotics venture to emerge from Singapore’s dynamic academic and clinical ecosystem. We now operate as a subsidiary of ZIG Ventures, a venture-builder with a keen focus on medical devices. Throughout the years, we have remained committed to pioneering advancements in prostate healthcare.
Our impact is being felt worldwide. Together with urologists we have already completed over 23,000 procedures globally, a milestone we are incredibly proud of.*
Global Reach
Biobot Surgical is proud to collaborate with urologists, hospitals and centres of excellence worldwide to bring cutting-edge technology to the forefront and shape the future of prostate technology on a global scale.
As part of our global expansion, Mona Lisa has been successfully introduced to surgeons in the US, China, Australia, Europe and Asia Pacific.
Asia
Chung Shan University Hospital, Taiwan
General Hospital, Singapore
Gleneagles Hospital Medini Johor
Hospital Umum Sarawak, Sarawak
Island Hospital, Penang
Life Care Diagnostics, Kuala Lumpur
Medical Centre, Subang Jaya
Mount Elizabeth Novena Hospital, Singapore
National University Hospital, Singapore
Ng Teng Fong General Hospital, Singapore
Raffles Hospital, Singapore
Sengkang General Hospital, Singapore
Singapore General Hospital, Singapore
Europe
Dünyam Hospital, Kayseri
Hirslanden Salem-Spital, Bern
Kolan international Hospital, Istanbul
New Clinic Bel Air, Bordeaux
Polyclinic Franche-Compté, Besançon
Santa Maria Nuova Hospital, Reggio Emilia
Siloah St. Trudpert Klinikum, Pforzheim
San Giacomo Hospital, Novi Ligure
University Hospital, Basel
University Hospital, Freiburg im Breisgau
University Hospital, Tübingen
Australia
Buderim Hospital, Sunshine Coast
Macquarie University Hospital, Sydney
Nepean Hospital, Sydney
St Vincent’s Private Hospital, Toowoomba
USA
Chicago, IL
Concord, MA.
Rochester, MN
San Antonio, TX
Our Team
Committed to driving change and innovation in prostate healthcare
Our success is anchored in a talented team specializing in robotic design, technology, medical image processing, software development and clinical applications.
Leadership Team
Albert
Lee
Chief Executive Officer
Kee Yew
Hwee
Chief Operations Officer
Chen
HongJun
Chief Technology Officer
Grace
Phee
Commercial Lead AP / EMEA
Siew
Neo
Commercial Operation, USA
Drew
Shaffer
VP, Sales USA
Board of Directors
Sim
Giok Lak
Chairman
Founder & Executive Chairman of Zicom Group & ZIG Ventures.
Sim
Kok Hwee
Deputy Chairman
CEO of ZIG Ventures & its nominated director for portfolio companies.
Yap
Chew Loong
Director
Serial angel investor & advisor to medtech startups. Director of ZIG Ventures.
He
Chao, PhD
Director
CEO of Microport Medbot. Top surgical robotics scientific leader in China.
Tony
Tan
Director
Serial healthcare entrepreneur and founder of Parkway Holdings.
Inventors
Chris
Cheng, MD
Singapore General Hospital
Henry
Ho, MD
Singapore General Hospital
John
Yuen, MD
Singapore General Hospital
Clinical Advisors
Christian
Wetterauer, MD
Head of Center of Excellence
Stefan
Kruck, MD
Siloah St. Trudpert Klinikum
Guo
Hongqian, MD
Nanjing Drum Tower
Tay
Kae Jack, MD
Singapore General Hospital
* As of Q1 2024.